Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Non-Small Cell Lung Carcinoma: early-phase trial registry
A small indexed set (7 trials) with no open enrollment listed right now.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · none currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent Non-Small Cell Lung Carcinoma: 7 US clinical trials tracked, none currently recruiting.
Recurrent Non-Small Cell Lung Carcinoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is University of Southern California, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-non-small-cell-lung-carcinoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 7 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Recurrent Non-Small Cell Lung Carcinoma has no open enrollment in this registry pull (7 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Non-Small Cell Lung Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Non-Small Cell Lung Carcinoma is recruiting below its size-band peers.
0 of 7 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Non-Small Cell Lung Carcinoma research.
University of Southern California accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Recurrent Non-Small Cell Lung Carcinoma enrolment sits around 94 participants.
Median target enrolment is 94 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.
-
Recurrent Non-Small Cell Lung Carcinoma research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NRG Oncology
NCT03137771
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
SWOG Cancer Research Network
NCT02438722
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
NCT02495896
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00698815
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00387465
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
NCT02581943
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
NCT03049618
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Non-Small Cell Lung Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Non-Small Cell Lung Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Non-Small Cell Lung Carcinoma page
7 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Recurrent Non-Small Cell Lung Carcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- University of Southern California sponsors the most Recurrent Non-Small Cell Lung Carcinoma trials on record, review their full trial history before evaluating a specific study. See University of Southern California's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Non-Small Cell Lung Carcinoma condition card totals 7 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.